Tolerability of Grazax in Patients With Hayfever in Real Life Settings

ALK-Abelló A/S628 enrolled

Overview

The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.

To assess the safety profile with Grazax according to the presence or not of polysensitization and/or asthma at enrollment

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

628

Conditions

Allergic Rhinoconjunctivitis

Interventions

GrazaxDRUG

1 tablet/day - pre and co-seasonal

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of grass pollen allergy * Positive skin prick-test and/or positive specific IgE to grass Exclusion Criteria: * Severe, unstable or uncontrolled asthma (FEV1\<70% of predicted value)

Locations (1)

Centre Hospitalier Universitaire

Nantes, France

Outcomes

Primary Outcomes

Adverse Events related to Grazax

All adverse events were reported according to the MedDRA dictionary

Time frame: From November 2007 to October 2010 (3 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.